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Abstract To determine the efficacy of pioglitazone to
prevent type 2 diabetes in older compared to younger
adults with pre-diabetes. Six hundred two participants
with impaired glucose tolerance (IGT) were randomized
in double blind fashion to placebo or pioglitazone for
diabetes prevention in the ACT NOW study (NEJM
364:1104–1115, 2011). Cox proportional hazard regres-
sion was used to compare time to development of dia-
betes over a mean of 2 years between older (≥61 years)
and younger participants. We compared effects of
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pioglitazone versus placebo on metabolic profiles, in-
flammatory markers, adipokines, β cell function (dispo-
sition index), insulin sensitivity (Matsuda index), and
body composition by ANOVA. Diabetes incidence was
reduced by 85 % in older and 69 % in younger subjects
(p = 0.41). β cell function (disposition index) increased
by 35.0 % in the older and 26.7 % in younger subjects
(p = 0.83). Insulin sensitivity (Matsuda index) increased
by 3.07 (5.2-fold) in older and by 2.54 (3.8-fold) in
younger participants (p = 0.58). Pioglitazone more ef-
fectively increased adiponectin in older versus younger
subjects (22.9 ± 3.2 μg/mL [2.7-fold] vs. 12.7 ± 1.4 μg/
mL [2.2-fold], respectively; p = 0.04). Younger subjects
tended to have a greater increase in whole body fat mass
compared to older subjects (3.6 vs. 3.1 kg; p = 0.061).
Younger and older subjects had similar decreases in
bone minera l dens i ty (0 .018 ± 0.0071 vs .
0.0138 ± 0.021 g/cm2). Younger and older pre-diabetic
adults taking pioglitazone had similar reductions in con-
version to diabetes and older adults had similar or great-
er improvements in metabolic risk factors, demonstrat-
ing that pioglitazone is useful in preventing diabetes in
older adults.
Keywords Geriatrics . Diabetes . Prevention .
Endocrinology
Background
The prevalence of diabetes increases dramatically with
age and it is estimated that 25–30 % of individuals over
the age of 65 have type 2 diabetes (Centers for Disease
Control and Prevention 2014). Impaired glucose toler-
ance (IGT) also is highly prevalent in older adults, affect-
ing ∼35 % of individuals >65 years (Cowie et al. 2009).
Further, individuals with IGT are at high risk of
converting to diabetes (5–10 % per year) (Tabak et al.
2012) and manifest similar pathophysiologic distur-
bances to individuals with type 2 diabetes (DeFronzo
2009). Diabetes is a major contributor to adverse health
outcomes with aging (Blaum et al. 2003) and is a signif-
icant predictor of disability (Gregg et al. 2000) and frailty
(Espinoza et al. 2012), both of which pose significant
public health burdens. Therefore, interventions to prevent
or delay diabetes in older adults are important in improv-
ing aging outcomes as the numbers of older adults who
either are living with diabetes or are at risk of developing
diabetes increases (Sloan et al. 2008).
Lifestyle modification and some anti-diabetic agents
(metformin, acarbose, liraglutide) have been useful in
preventing diabetes in prediabetic adults at high risk of
developing diabetes (Chiasson et al. 2002; DeFronzo
et al. 2011; Diabetes Prevention Program Research
Group 2002; Pi-Sunyer et al. 2015). Thiazolidinediones
also delayed diabetes progression among subjects
with IGT in three placebo-controlled multicenter tri-
als (Buchanan et al. 2002; DeFronzo et al. 2011;
DREAM Trial Investigators et al. 2006). In the
ACT NOW Study, pioglitazone reduced the conver-
sion of IGT to diabetes by 72 % (DeFronzo et al.
2011).
To design and apply strategies to prevent type 2
diabetes in older adults, it is necessary to determine
whether interventions that delay diabetes in the general
population are equally effective as people age. A sec-
ondary analysis of the Diabetes Prevention Program
(DPP) showed that older adults (ages 60 to 85 years)
were more responsive to intensive lifestyle intervention
than to metformin, compared to younger adults (ages 25
to 59) (Diabetes Prevention Program Research Group
2006), as determined by oral glucose tolerance testing.
These findings were thought to be, in part, related to the
greater weight loss and more active participation in
lifestyle modification activities among older participants
and possibly related to differences in the pathophysiol-
ogy of insulin resistance in aging individuals (Basu et al.
2003).
The goal of the present study was to evaluate whether
aging modifies the effectiveness of pioglitazone for the
prevention of diabetes. For this purpose, we compared
responses between older (ages 61 through 86 years) and
younger (ages 18 through 60 years) subjects in the ACT
NOW trial.
Methods
Subjects Subjects were 602 participants from the ACT
NOW trial aged 18 or older. We selected the cut point of
ages 61 through 86 years for the older group and ages 18
through 60 years for the younger group because age 61
corresponds to the top 25th percentile for age distribu-
tion in this study sample. Patients were eligible for the
ACT NOW study if they had a fasting plasma glucose
concentration between 95 and 125 mg/dl (5.3 and
6.9 mmol/l) and at least one other risk factor for diabetes
(DeFronzo et al. 2009). All subjects had IGT, defined as
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a 2-h plasma glucose between 140 and 199 mg/dl [7.8 to
11.0 mmol/l] during a single oral glucose tolerance test
(OGTT) (American Diabetes Association 2008) as pub-
lished previously (DeFronzo et al. 2009, 2011).
The first participant was recruited in January
2004 , a nd en r o l lmen t wa s comp l e t e d i n
March 2006. Participants were followed until they
reached the primary end point of diabetes, withdrew
from the study, were lost to follow-up, or completed
the study.
Study design The study design and protocol have been
described previously (DeFronzo et al. 2009). Briefly,
eight centers participated in this investigator-initiated
study, which was approved by the Institutional Review
Board at each site. Written informed consent was ob-
tained from all participants. All results were transmitted
to the Data Coordinating Center in Phoenix, Arizona,
where they were recorded and audited and then sent to
the Data Analysis Center in San Antonio. Takeda Phar-
maceuticals provided financial support for the study but
had no access to the data. After eligibility for the study
was ascertained, participants underwent randomization
according to center and sex. Subjects received 30 min of
dietary instruction consistent with the goals of the DPP
(Diabetes Prevention Program Research Group 2002).
After enrollment, participants were asked to fast
overnight and a 75-g OGTT was performed at ∼8 a.m.
the next day. Plasma samples were collected every
15 min for 2 h for measurement of plasma glucose and
insulin concentrations. Additional baseline assessments
included measurements of blood pressure, height,
weight, waist circumference, hemoglobin A1c (HbA1c),
and lipids. Dual-energy X-ray absorptiometry (DEXA)
scans were performed using a Hologic QDR 4500A
instrument (Watertown, MA, USA) as previously de-
scribed (Bray et al. 2013). Five of the eight study centers
participated in the DEXA substudy, which had 232
participants.
Following completion of the OGTT, participants re-
ceived pioglitazone 30 mg/day or a placebo. After
1 month, the dose of pioglitazone was increased to
45 mg/day as tolerated. Participants returned at 2, 4, 6,
8, 10, and 12 months during the first year of the study
and every 3 months thereafter. At each visit, weight,
blood pressure, and pulse were measured and the extent
of edema was graded as described (DeFronzo et al.
2011). Fasting plasma glucose was measured at each
follow-up visit. HbA1c and plasma lipids were
measured every 6 months, and the OGTT was repeated
annually. Plasma C-reactive protein (CRP), monocyte
chemotactic protein (MCP)-1, plasminogen-activating
inhibitor (PAI)-1, tumor necrosis factor (TNF)-α, inter-
leukin (IL)-6, leptin, and adiponectin were measured at
baseline and at study end.
Conversion of impaired glucose tolerance to
diabetes The primary outcome was the development
of diabetes (defined as a fasting plasma glucose lev-
el ≥ 126 mg/dl [≥7.0 mmol/l] or a 2-h glucose lev-
el ≥ 200 mg/dl [11.1 mmol/l]); a repeat OGTT was
performed to confirm the diagnosis. If the diagnosis
was not confirmed, participants continued their assigned
therapy.
Calculations Insulin sensitivity (Matsuda index) was
derived from plasma glucose and insulin measurements
obtained during the OGTT as previously described
(Matsuda and DeFronzo 1999). β cell function was
determined with the insulin secretion/insulin resistance
(disposition) index calculated as (ΔI0–120/ΔG0–
120) × (Matsuda index) during the OGTT, where ΔI0–
120/ΔG0–120 represents the increment in plasma insu-
lin and glucose concentrations during the 120-min
OGTT (Abdul-Ghani et al. 2006). Plasma glucose,
insulin, lipids, HbA1c, CRP, MCP-1, PAI-1,
TNF-α , IL-6, lept in, and adiponect in were
measured as previously described (DeFronzo et al.
2013, 2009).
Statistical analysis Baseline characteristics were exam-
ined by age group (stratified according to age: ≥ 61 years
vs. <61) using chi-squared tests for categorical variables
and t tests for continuous variables. Linear regression
analysis was used to examine study outcomes in re-
sponse to pioglitazone versus placebo at study end by
age group. Outcomes assessed were change in insulin
sensitivity (Matsuda index), fasting plasma glucose,
fasting insulin, lipids, HbA1c, adipokines, and markers
of inflammation. Additional regression analyses were
performed with covariate adjustment for sex and base-
line value of each individual outcome (i.e., change in
adiponectin was adjusted for sex and baseline
adiponectin value). Log transformation was used for
non-normally distributed outcome variables. Cox pro-
portional hazard models were used to examine time to
diabetes conversion by age category. These analyses
were adjusted for sex and baseline measures.
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Results
Subject characteristics Baseline data stratified by age
and treatment assignment are shown in Table 1. There
were no significant differences between groups in either
the young or older participants for any characteristics.
Overall, regardless of treatment assignment, older par-
ticipants were more likely to be female (56 vs. 36 %,
p < 0.001), but did not differ by race or ethnic group
compared to younger participants. At baseline, older
participants had lower BMI (32.5 ± 5.0 vs.
35.0 ± 6.5 kg/m2, p < 0.0001), higher systolic blood
pressure (134 ± 16 vs. 126 ± 16 mmHg, p < 0.0001),
lower fasting insulin (8.9 ± 8.3 vs. 11.4 ± 9.1 μ U/mL,
p < 0.001), lower LDL cholesterol (99 ± 28 vs.
108 ± 31 mg/dL, p = 0.001), higher HDL cholesterol
(42 ± 11 vs. 40 ± 10 mg/dl, p = 0.007), and lower total
cholesterol (166 ± 33 vs. 173 ± 35 mg/dL, p = 0.028)
compared to younger participants. Overall, compared to
younger participants, older participants had
slightly higher insulin sensitivity as measured by the
Matsuda index at baseline (4.4 ± 2.7 vs. 3.8 ± 2.7,
p = 0.0008).
There were no significant differences in plasma in-
flammatory biomarkers between pioglitazone and pla-
cebo groups in the young versus older age groups.
However, older participants had higher plasma IL-6
(4.7 ± 18.0 vs. 4.4 ± 35.4 pg/mL, p = 0.030), MCP-1
(158 ± 64 vs. 130 ± 54 pg/mL, p < 0.0001), TNF-α
(4.8 ± 1.8 vs. 3.9 ± 2.8 pg/mL, p < 0.0001), and
adiponectin (13.0 ± 7.6 vs. 11.1 ± 7.2 μg/mL,
p = 0.0011) concentration at baseline. There were no
overall age differences in circulating levels of leptin,
PAI-1, or CRP compared with younger participants.
Baseline body composition and bone density data for
participants in the DEXA substudy are shown in Sup-
plemental Table 1. Older subjects had higher whole
body fat percentage (41.9 ± 6.2 vs. 38.8 ± 7.8 %,
p = 0.023) and lower bone mineral density
(0.95 ± 0.09 vs. 1.02 ± 0.11 g/cm2, p = 0.0025) com-
pared to younger participants.
Effect of treatment on conversion to diabetes As previ-
ously reported, pioglitazone reduced the incidence of
diabetes by 72 % overall (HR = 0.28, 95 % CI 0.16–
0.49; p < 0.001) (10). After adjustment for age and
sex, this finding did not change significantly
(HR = 0.29, 95 % CI 0.16–0.49; p < 0.01). In older
participants, diabetes incidence was reduced by 84 %
(HR = 0.16, 95% CI 0.05–0.50; p < 0.01); and in
younger subjects diabetes incidence was reduced by
69 % (HR = 0.31, 95% CI 0.17–0.57, p < 0.01)
(Fig. 1). Diabetes incidence did not differ by age
(p = 0.41).
Effect of pioglitazone on laboratory and physiologic
parameters As previously reported, pioglitazone re-
duced fasting plasma glucose, insulin, hemoglobin
A1c, triglycerides, PAI-1, IL-6, TNF-α and increased
insulin sensitivity, plasma high density lipoprotein
(HDL), and adiponectin in the overall cohort
(DeFronzo et al. 2013, 2011; Saremi et al. 2013). For
all indices in the unadjusted analyses, older and youn-
ger adults responded similarly to pioglitazone (Fig. 2
and Supplemental Table 3). However, in analyses ad-
justed for sex and baseline value, adiponectin was
increased more in older compared to younger subjects
taking pioglitazone (22.94 ± 3.19 μg/mL [2.72-fold
increase] vs. 12.70 ± 1.43 μg/mL [2.23-fold increase],
p = 0.04). In pioglitazone-treated subjects, β cell func-
tion (disposition index) increased by 0.98 (1.2-fold) in
older adults (p = 0.08) and by 1.2 (1.19-fold) in
younger subjects (p < 0.01). There was no difference
in response by age group (p = 0.74). Pioglitazone
improved insulin sensitivity (Matsuda index) in the
overall cohort (DeFronzo et al. 2011). The Matsuda
index of insulin sensitivity increased to 3.07 (5.2-fold
increase) in older adults taking pioglitazone versus
placebo (p < 0.01) and to 2.54 (3.8-fold increase) in
younger subjects (p < 0.01); however, there was no
significant difference in increased insulin sensitivity in
older versus younger subjects taking pioglitazone
(p = 0.58).
Body composition Pioglitazone increased whole body
fat mass in the overall ACT NOW cohort (Bray et al.
2013), and the increment from baseline in body fat was
similar in younger (by 3.62 ± 0.63 kg [2.6-fold],
p < 0.001) and older (by 3.10 ± 1.6 kg [2.6-fold],
p = 0.061) subjects (p = 0.751 between groups)
(Supplemental Table 3). Pioglitazone reduced total body
bone mineral density in the overall cohort (Bray et al.
2013). The decrease in total bone mineral density with
p i og l i t a zone was s im i l a r i n younge r ( by
0.018 ± 0.0071 g/cm2, p = 0.013) and older (by
0.0138 ± 0.021 g/cm2, p = 0.521) subjects. However,
this effect did not differ by age group (p = 0.835 be-
tween groups).
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Table 1 Characteristics by treatment and age groups at study baseline



























Age 47.4 (8.6) 46.2 (9.2) 0.083 65.9 (4.9) 66.3 (4.9) 0.637 52.3 (11.8) <0.0001
Race 0.240 0.809
White 161 (75.2) 178 (80.9) 72 (81.8) 67 (83.8) 478 (79.4) 0.8094
Black 44 (20.6) 34 (15.5) 13 (14.8) 11 (13.8) 102 (16.9)
Asian 5 (2.3) 8 (3.6) 2 (2.3) 2 (2.5) 17 (2.8)
Pacific Islander 1 (0.5) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.2)
Native American 2 (0.9) 0 (0.0) 1 (1.1) 0 (0.0) 3 (0.5)
Other 1 (0.5) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.2)
Sex, female 80 (37.4) 78 (35.5) 0.676 47 (53.4) 47 (58.8) 0.486 252 (41.9) <0.001
Pioglitazone group 302 (50.2) 0.5583
BMI (kg/m2) 34.6 (6.4) 32.3 (6.7) 0.333 32.5 (5.1) 32.5 (5.0) 0.996 34.3 (6.2) <0.0001
Body surface area (m2) 2.1 (0.3) 2.1 (0.3) 0.317 2.1 (0.2) 2.1 (0.2) 0.471 2.10 (0.25) 0.0710
Waist circumference (cm) 106.3 (14.1) 107.7
(15.1)









0.893 131.5 (15.5) 136.4
(16.3)
0.047 128 (16) <0.0001
Diastolic blood pressure
(mmHg)
74.5 (9.9) 74.0 (10.4) 0.578 72.4 (8.1) 74.2 (10.2) 0.220 74 (10) 0.3395
Fasting plasma glucose (mg/
dL)
104.7 (7.9) 104.7 (7.9) 0.961 104.9 (7.0) 104.0 (7.1) 0.389 105 (8) 0.7677
Fasting insulin (mU/mL) 11.1 (8.2) 11.6 (9.9) 0.565 9.1 (9.1) 8.8 (7.5) 0.835 10.7 (8.9) <0.001
Hemoglobin A1c (%) 5.5 (0.4) 5.5 (0.4) 0.741 5.6 (0.5) 5.5 (0.4) 0.130 5.5 (0.4) 0.126
Hemoglobin A1c
(mmol/mol)
36 36 38 36 36
Triglycerides (mg/dL) 125.8 (63.5) 119.1
(56.0)
0.253 118.0 (47.3) 123.9
(65.4)
0.506 122 (59) 0.9569
Total cholesterol (mg/dL) 171.0 (34.6) 173.9
(35.5)
0.400 162.6 (32.4) 168.8
(33.6)
0.229 171 (35) 0.0282
HDL cholesterol (mg/dL) 39.7 (10.3) 39.7 (10.1) 0.978 41.3 (11.6) 43.5 (10.9) 0.210 40 (11) 0.0073
LDL cholesterol (mg/dL) 106.2 (30.7) 110.3
(31.8)





Matsuda index 3.7 (2.6) 3.8 (2.6) 0.894 4.4 (2.5) 4.4 (3.0) 0.914 3.9 (2.6) 0.0008
Disposition index 3.2 (1.9) 3.2 (1.9) 0.933 3.4 (1.6) 3.4 (1.5) 0.865 3.23 (1.79) 0.1206
Glucose area under the curve
during 120 min OGTT
1.1 (0.6) 1.1 (0.7) 0.913 1.0 (0.6) 1.0 (0.6) 0.440 1.05 (0.6) 0.1599
IL-6 (pg/mL) 7.2 (50.4) 1.7 (1.6) 0.188 7.2 (24.9) 2.1 (1.4) 0.121 4.5 (31.3) 0.0304
Leptin (pg/mL) 35.6 (23.1) 36.7 (25.7) 0.719 34.2 (26.3) 34.8 (27.9) 0.908 35.7 (25.2) 0.086
MCP-1 (pg/mL) 136.9 (56.6) 123.7
(51.4)
0.038 156.4 (71.4) 159.2
(55.8)
0.811 138 (59) <0.0001
TNF-α (pg/mL) 4.2 (3.7) 3.7 (1.6) 0.152 4.9 (1.9) 4.7 (1.6) 0.506 4.2 (2.6) <0.0001
Adiponectin (μg/mL) 11.0 (6.7) 11.1 (7.8) 0.860 12.6 (7.0) 13.6 (8.2) 0.454 11.7 (7.4) 0.0011
PAI-1 (ng/mL) 15.1 (8.8) 15.9 (8.3) 0.400 15.1 (12.2) 13.6 (5.9) 0.404 15.2 (8.9) 0.288
CRP (mg/L) 3.4 (3.9) 3.1 (3.8) 0.695 4.9 (4.9) 2.7 (2.9) 0.264 3.4 (3.9) 0.9667
a p value for age difference between young and older participants across treatment groups
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Adverse events Adverse events were low in both groups
(Supplemental Table 4). No differences between groups
were seen with respect to changes in peripheral edema,
hematuria, body mass index, waist circumference, or
fractures or other adverse events. There were also no
age group differences in the incidence of adverse events.
Discussion
Older adults are at increased risk of developing diabetes,
and those with IGTare at the highest risk. In this study, we
examined whether the efficacy of pioglitazone for diabetes
prevention and metabolic responses differed by age. Over-
all, older and younger participants had similar responses
for most outcomes. Notably, pioglitazone was highly ef-
fective in reducing conversion to diabetes in older subjects,
similar to responses in younger individuals.
Age-dependent declines in both β cell function and
insulin sensitivity play major roles in the deterioration of
glucose homeostasis that occurs with advancing age
(Chang et al. 2006; Ghosh et al. 2011). Pioglitazone is
thought to improve β cell function and ameliorate insulin
resistance through its action on the peroxisome
proliferator-activated receptor (PPAR)-γ (DeFronzo et al.
2013). We previously showed that the risk of developing
diabetes in the ACT NOW Study was closely related to
waning β cell function as determined by the insulin
secretion/insulin resistance (IS/IR) index and that an im-
proved IS/IR index with pioglitazone was the strongest
predictor for reduced risk of conversion to diabetes. In the
present study, the IS/IR index improved similarly in older
and younger adults. Thus, while β cell function seems to
decline progressively with advancing age (Chang et al.
2006), β cells from older participants still responded ap-
propriately to the PPAR-γ agonist. Similarly, in older and
younger subjects, pioglitazone was equally effective in
improving insulin sensitivity, a major factor contributing
to diabetes prevention (DeFronzo et al. 2009, 2011).
While lifestyle intervention remains the preferred
initial recommendation for subjects with pre-diabetes
and was highly effective in the DPP, not all older adults
can achieve the goals of lifestyle intervention due to
chronic disease, pain, and/or disability. Therefore, many
older adults with pre-diabetes remain at risk for diabetes
despite lifestyle intervention; in such people, pharmaco-
therapy for diabetes prevention may be appropriate.
However, it remains unknown whether older adults with
pre-diabetes are appropriate candidates for preventative
pharmacotherapies—and among those therapies, which
are most effective in preventing diabetes in older adults.
Current clinical guidelines from the American Diabe-
tes Association and the American Geriatrics Society do
not recommend pharmacologic agents for diabetes pre-
vention in prediabetic adults over 60 years old (American
Diabetes Association 2014). This recommendation re-
sults, in part, from a subanalysis of the DPP study which
showed that, although older and younger adults
responded to metformin, intensive lifestyle modification
was significantly more effective than metformin in im-
proving glucose tolerancewith advancing age, as assessed
by OGTT (Diabetes Prevention Program Research Group
2006). However, when conversion of pre-diabetes to
Fig. 1 Kaplan-Meier curve for
time to conversion to diabetes by
treatment group (pioglitazone vs.
placebo) and age group (age ≥ 61
vs. <61 years)
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diabetes was determined by an HbA1c ≥ 6.5 %, metfor-
min was equally effective in older and younger subjects
(Diabetes Prevention Program Research Group 2015).
These data (Diabetes Prevention Program Research
Group 2002; Sloan et al. 2008), along with the results
presented here, indicate that both pioglitazone and
metformin offer an alternative to delay/prevent diabetes
in older subjects at high risk of developing diabetes.
It remains to be determinedwhether metforminmight
be preferable as a preventive therapy in older adults
because of its other potentially beneficial anti-aging


















































































































Fig. 2 Change with pioglitazone compared to placebo in: a dis-
position index, b Matsuda index, c hemoglobin A1c (HBA1c), d
adiponectin, e diastolic blood pressure(DBP), f systolic blood
preassure (SBP), g total body fat mass, h total bone mineral
density by age group. The open boxes indicate the younger age
group (age < 61 years) and the filled boxes represent the older age
group (age ≥ 61 years)
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question. However, evidence from animal studies sug-
gests that metformin has aging-modulating properties
such as lifespan extension (Martin-Montalvo et al.
2013), improved exercise tolerance and healthspan
(Martin-Montalvo et al. 2013), and reduced incidence
of cancer (Berstein 2012; DeCensi et al. 2010).
The incidence of adverse events was similar in both
age groups for all outcomes. InACTNOW, pioglitazone
was associated with a small decrease in bone mineral
density in the pelvis in men and women and decreased
bone mineral density in the thoracic spine and ribs of
women and in the lumbar spine and legs of men. How-
ever, the rate of fractures was similar in pioglitazone
versus placebo groups (Bray et al. 2013; DeFronzo et al.
2011). Another study indicated that thiaozolidinediones
increase fracture risk in postmenopausal women but not
men (Zhu et al. 2014). Until there is more clarity about
the interplay between aging, bone loss, and
thiaozolidinediones, these agents should be used with
caution in older subjects, particularly women.
Many issues need to be resolved before advocating
routine use of thiaozolidinediones for diabetes prevention
in older subjects. First, there is no evidence that pharma-
cologic treatment of pre-diabetes/impaired glucose toler-
ance or mild diabetes in older subjects improves overall
morbidity and mortality. Second, the potential toxicity and
adverse effects of thiaozolidinediones in older adults re-
main unclear. In addition to reduced bone density and
possible increases in fracture risk, edema and heart failure
are well-known adverse effects of thiaozolidinediones.
However, in ACT NOW, overall rates of these adverse
effects were low and not affected by age. Moreover, older
subjects typically take many drugs, and adding another
medication could increase the risk of harmful interactions.
Thus, risks/benefits should be carefully assessed in every
patient, particularly older adults, before prescribing drugs
to prevent and treat mild diabetes (American Geriatrics
Society Expert Panel on the Care of Older Adults with
Diabetes Mellitus 2013). For example, an older adult who
takes few medications and has good functionality and life
expectancy, but shows signs of early microvascular dam-
age (i.e., retinopathy or macroalbuminuria), may potential-
ly benefit from an intervention for diabetes prevention/
early treatment. On the other hand, in an older patient with
limited life expectancy who is already taking multiple
drugs, risks of additional treatment with pioglitazone may
outweigh any potential benefit. Most importantly, more
research in this area is required in order to make substan-
tiated recommendations.
In summary, older prediabetic adults demonstrated
similar reductions in conversion to diabetes and similar
or better improvements in metabolic risk factors with
pioglitazone compared to younger counterparts. Pioglit-
azone may be a useful pharmacologic agent to prevent
diabetes in older adults.
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